Conditions: Dyslipidemia Kidney Disease
Keywords: Dyslipidemia Kidney Disease
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 280
Healthy volunteers: no

Brief summary:
The objective of this study is to evaluate the safety and efficacy of the combination of ABT-335 plus rosuvastatin in dyslipidemic subjects with Chronic Kidney Disease (CKD) Stage 3.

Detailed description:

Arms:
arm 1: ABT-335 45 mg plus rosuvastatin 5 mg for 8 weeks, then ABT-335 45 mg plus rosuvastatin 10 mg for 8 weeks arm 2: Rosuvastatin 5 mg for 8 weeks then rosuvastatin 10 mg for 8 weeks

Interventions: intervention 1: ABT-335 plus rosuvastatin intervention 2: Rosuvastatin
Intervention descriptions: intervention 1: ABT-335 45 mg plus rosuvastatin 5 mg for 8 weeks, then ABT-335 45 mg plus rosuvastatin 10 mg for 8 weeks intervention 2: Rosuvastatin 5 mg for 8 weeks then rosuvastatin 10 mg for 8 weeks

Protocol document: